Postoperative Parenteral Nutrition Support and Neoadjuvant Chemotherapy Combined with Cytoreductive Surgery Improve the Quality of Life, but Not the Survival Rate or Incidence of Complications

We have explored the efficacy of neoadjuvant chemotherapy in association with cytoreductive surgery and postoperative parenteral nutrition support in advanced ovarian cancer patients. The control group received cytoreductive surgery combined with postoperative conventional chemotherapy and fasted after surgery, whereas the treatment group received neoadjuvant chemotherapy combined with cytoreductive surgery and parenteral nutrition. In contrast to the control group, the operation time, hospital stay, amount of intraoperative blood loss, and abdominal fluid accumulation of the treatment group were diminished, the total effectiveness rate was elevated, serum levels of albumin, transferrin, and prealbumin were increased, levels of human epididymal protein 4, vascular endothelial growth factor, and carbohydrate antigen 125 were declined, and the Karnofky Performance Status score was higher. While there was no difference observed in the 1-year survival rate or total incidence of complications between the two groups, the quality of life of patients in the treatment group improved.